
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
You can’t take part in stage A2
In stage A2 the team need up to 20 people to join.
You have cisplatin as a drip into a vein. You have it over 2 hours. You have it once every 3 weeks. Each 3 week period is called a cycle of treatment. You have up to 6 cycles of cisplatin.
Capecitabine is a tablet. You take it twice a day during the cycles of cisplatin treatment. You take capecitabine within 30 minutes after eating. Your doctor will tell you how many tablets you must take.
You have M6620 once or twice each week. You have M6620 as a drip into a vein. It takes between 1 and 1½ hours. Your doctor will tell you how often you are to have M6620. This will be either once or twice a week.
In stage B the team need up to 25 people to join.
You have treatment with cisplatin and M6620 every 3 weeks. Each 3 week period is called a cycle of treatment.
Before starting radiotherapy, you have 2 cycles of treatment with cisplatin and M6620. You have cisplatin at the start of each cycle.
You have M6620 the day after you have cisplatin (2nd day of the treatment cycle). How often you have M6620 will depend on when you agree to join the study.
You take capecitabine twice a day every day during the first 2 cycles of treatment of cisplatin. You take capecitabine within 30 minutes after eating. Your doctor will tell you how many tablets you must take.
You have radiotherapy Monday to Friday for 5 weeks. During radiotherapy you have cisplatin at the start of each 3 week period of treatment (a cycle of treatment).
You have M6220 an hour after radiotherapy on the 2nd day of each cycle. This may be more regular depending on when you join the study.
When you start radiotherapy, you take capecitabine twice a day on the days you have radiotherapy, Monday to Friday. You don’t take capecitabine on Saturday or Sunday.
Blood and tissue samples
People in stage A2 and stage B will have extra blood samples taken.
The study team will use these blood samples to understand how M6620 affects your body and the cancer cells.
People in stage B will also have 2 extra samples of tissue taken from their cancer. The team will use these to find out how M6620 affects the cancer cells.
When you agree to join stage A2 or stage B you must also agree to have these blood and tissue samples taken.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Maria Hawkins
Cancer Research UK
CRUK/MRC Oxford Institute for Radiation Oncology
Experimental Cancer Medicine Centre (ECMC)
Merck KGaA
University of Oxford
This is Cancer Research UK trial number CRUKD/15/011.
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.